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Background: Previous evidence has shown that the FOXP3 gene was involved in the pathogenesis of several
tumors; however, the correlation between single nucleotide polymorphisms (SNPs) in the FOXP3 gene and the
susceptibility to hepatitis B-related hepatocellular carcinoma (HCC) remains unclear.
Methods: We analyzed two SNPs in the FOXP3 gene, rs2280883 and rs3761549, in 392 patients with HCC, 344
patients with chronic hepatitis B (CHB) and 372 matched healthy controls. Genotyping was performed by MALDI-TOF
Mass Spectrometry for all donors.
Results: Compared to healthy controls, HCC patients had higher frequencies of the TT genotype (79.6%) at
rs2280883 and the CC genotype (77.6%) at rs3761549 of the FOXP3 gene; CHB patients also had higher
frequencies of the TT genotype (74.1%) at rs2280883 and the CC genotype (74.6%) at rs3761549. There were no
significant differences in the distribution of FOXP3 genotypes between CHB donors and HCC donors. The TT
genotype at rs2280883 was more frequent in patients with HCC than healthy donors (P = 0.01), but no significant
difference was observed in this genotype between CHB and healthy donors (P = 0.479). C allele frequency at
rs3761549 was higher in HCC patients than healthy donors (P = 0.03), but distribution of this allele was not
significantly different between CHB patients and healthy donors (P = 0.11). Stratified analysis showed that the CC
genotype at rs3761549 was significantly associated with a high incidence of portal vein tumor thrombus (P = 0.02)
and that the TT/CT genotype at rs3761549 was significantly associated with an increased rate of tumor recurrence
in HCC patients (P = 0.001).
Conclusions: Our results suggested that the FOXP3 gene polymorphisms at rs2280883 and rs3761549 may be
associated with hepatitis B-related HCC. At rs3761549, the CC genotype and the TT/CT genotype were associated
with a high incidence of portal vein tumor thrombus and tumor recurrence, respectively.
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Hepatocellular carcinoma is the sixth most common ma-
lignancy and the third most common cause of cancer-
related death worldwide [1], but the disease progression
of HCC remains poorly understood. A previous study
showed that the local tumor immune microenvironment* Correspondence: chenhongsong@pkuph.edu.cn
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reproduction in any medium, provided the orplays an important role in cancer suppression and
promotion and that one of the main factors leading to
tumor immune tolerance in the local tumor microenvi-
ronment is the influence of CD4+/CD25+/FOXP3+ regu-
latory T cells (Tregs) [2]. The number of Tregs increases
in response to infection by pathogenic microorganisms,
including the hepatitis B virus; this increase inhibits
CD4+ and CD8+ T-cell activation, proliferation and cyto-
kine secretion, thus affecting the host immune response to
infection and leading to chronic infection [3-6]. This
phenomenon indicates that the FOXP3 gene may play atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hepatitis B, which may increase the risk of carcinoma.
FOXP3 is a specific molecular marker of Tregs that
plays an important role in the development of Tregs and
their inhibitory functions [7,8]. Increased levels of
FOXP3+ Tregs in the peripheral blood and tumor tissue
have been reported in patients with various types of can-
cer, including ovarian [9,10], breast [11], hepatocellular
carcinoma [12] and other tumors [13]; the accumulation
of Tregs in local lymph nodes or in tumors is associated
with a less favorable prognosis [9-14]. Although Tregs
are the major cell type expressing FOXP3, it has recently
been demonstrated that the tumor cell itself can express
FOXP3, such as pancreatic cancer [15], melanoma [16]
and other tumor types [17], and the function of FOXP3
may represent a new mechanism of immune evasion in
cancers.
It has been confirmed that genetic polymorphisms in
FOXP3 are related to the development of autoimmune
diseases, such as allergic rhinitis [18], idiopathic infertility
and endometriosis-related infertility [19]. These results
suggested that polymorphisms at rs2280883 within the
FOXP3 gene may be associated with idiopathic infertility,
while polymorphisms at rs3761549 may be related to
endometriosis. However, it remains unclear whether
FOXP3 gene polymorphism is associated with hepatitis
B-related HCC.
Based on FOXP3 gene SNP genotype data from the
HapMap Phase II + Phase III database, two tagSNPs,
rs2280883 and rs3761549, were selected for genotyping
because these two SNPs could cover 80% of the MAF
> 0.1 SNPs. To investigate the correlation between spe-
cific SNPs in the FOXP3 gene and hepatitis B-related
HCC, Matrix-Assisted Laser Desorption/Ionization
Time of Flight (MALDI-TOF) Mass Spectrometry was
used to screen for the presence of the FOXP3 gene
polymorphisms in HCC donors, CHB donors and
healthy donors. Here, we present data describing an
association between FOXP3 genetic variation and sus-
ceptibility to hepatitis B-related HCC in all donors.
Materials and methods
Study subjects and peripheral blood samples
Peripheral blood samples were obtained from 392 HCC
patients, 344 CHB patients and 372 healthy donors.
HCC patients were treated at the Guilin Medical
University-affiliated hospital between November 2001
and April 2010. CHB patients with diagnoses conformed
to the latest diagnostic criteria [20] were from the
Peking University Hepatology Institute (Peking, China)
between November 2001 and April 2010. Healthy
donors were patients undergoing routine physical exami-
nation at Peking University People’s Hospital. General
patient information was recorded in detail, including age,gender, alcohol abuse, cirrhosis, presence of hepatitis B or
hepatitis C virus (HCV) infection, alpha-fetoprotein
(AFP), alanine aminotransferase (ALT), aspartate amino-
transferase (AST), γ-glutamyl transpeptidase (GGT) and
total bilirubin (TBIL) levels; this information is provided
in Table 1. HCC patient information, such as primary
tumor size, histologic tumor type, histologic grade, lymph
node (LN) stage, portal vein thrombosis and distant
metastasis, were routinely assessed according to the TNM
staging criteria proposed in 2002 by the International
Union against Cancer (UICC) and American Joint Com-
mittee on Cancer (AJCC). All CHB patients have been
screened by B-ultrasound and CT examination to exclude
cancers. Healthy donors were selected at random; none
had HBV and HCV infection according to screening for
HBsAg and anti-HCV, and donors with liver cirrhosis or
tumor-related diseases were excluded by B-ultrasound and
CT examination. The study was implemented after recei-
ving the approval of the Medical Ethics Committee of
Peking University People’s Hospital. Written informed
consent was obtained from all patients prior to sample
collection according to the Declaration of Helsinki in 1995
(as revised in Tokyo, 2004).
FOXP3 SNP genotyping
FOXP3 gene SNP genotype data were retrieved from the
HapMap Phase II + Phase III database, and the haplotypes
were analyzed with restrictive standards (r2 > 0.8 and a
minimum allele frequency (MAF) > 0.1) in Haploview 4.2
software. Finally, two tagSNPs, rs2280883 and rs3761549,
which were able to cover 80% of the MAF > 0.1 SNPs,
were selected for genotyping. DNA was extracted from
the peripheral blood samples from each patient using
standard methods. Genotyping was performed by
MALDI-TOF Mass Spectrometry for all donors. The
DNA from the donors was blinded, coded and tested
using a 384-well format SpectroCHIP microarray. PCR
primers and single base extension primers for rs2280883
and rs3761549 were designed using Sequenom Assay
design 3.1 software. These primer sequences are shown in
Table 2. A MALDI-TOF Mass Spectrometer was used for
data acquisition from the SpectroCHIP. The results were
analyzed using Sequenom MassARRAY RT software.
Statistical analysis
ALT, AST, GGT, TBIL and AFP levels were reported as
the mean ± standard deviation, and the distributions of
these variables were compared by Kruskal-Wallis tests;
AFP values between HCC and CHB donors were com-
pared by the Mann–Whitney U test. Patients’ age, gender,
alcohol abuse and genotype frequencies were obtained by
direct counting and statistical analysis was performed by
the chi-squared test. Odds of allele and genotype with 95%
confidence intervals (95% CI) in patients with HCC versus
Table 1 Demographic, clinical and biological characteristics of all donors
Characteristics HCC n(%) CHB n(%) HEAL n(%) P value
n = 392 n = 344 n = 372
Age <55 252(64.3) 223(64.8) 245(65.9) 0.90
≥55 140(35.7) 121(35.2) 127(34.1)
Gender Male 345(88.0) 267(77.6) 306(82.3) 0.001
Female 47(12.0) 77(22.4) 66(17.7)
Alcohol abuse Absent 75(19.1) 44(12.8) 31(8.3) <0.001
Present 317(80.9) 300(87.2) 341(91.7)
Cirrhosis Absent 50(12.8) 331(96.2) 372
Present 342(87.2) 13(3.8) 0
Anti-HCV positive 0 0 0
HBsAg positive 364(92.9) 344(100.0) 0
AFP(ng/ml) 923.3 ± 597.1 7.6 ± 6.9 <0.001
ALT(IU/L) 51.0 ± 24.0 54.0 ± 41.0 21.0 ± 8.1 0.30
AST(IU/L) 36.3 ± 29.4 45.3 ± 34.3 26.1 ± 6.9 0.67
GGT(IU/L) 27.7 ± 23.5 39.4 ± 35.7 19.5 ± 17.1 0.56
TBIL(μmol/L) 16.4 ± 12.6 19.0 ± 7.3 12.1 ± 4.2 0.56
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transpeptidase (GGT) and total bilirubin (TBIL), Alpha Fetoprotein (AFP).
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than 0.05 were considered statistically significant. SPSS
13.0 for Windows was used for all statistical calculations.
Results
The distribution of demographic and clinical
characteristics of all donors
As shown in Table 1, there were no significant diffe-
rences in the age, AST, ALT, GGT, and TBIL levels be-
tween either HCC or CHB groups and the healthy group
(all P > 0.05). HBsAg was undetected in all healthy do-
nors, but 92.9% of HCC patients were HBsAg positive;
all these donors were anti-HCV negative. The AFP level
and the frequency of cirrhosis were significantly higher
in the HCC group than in the CHB group. The distribu-
tions of gender and alcohol abuse showed that male
alcohol-abusing donors accounted for the majority of
the HCC, CHB and healthy donors. All donors were
placed into the three groups based on the principle of
random sampling; these characteristics showed the true
representative natural history of the incidence of CHB
and HCC in China.Table 2 Sequences of PCR primers and single-base extension





“F”: Forward, “R”: Reverse.The analysis of FOXP3 SNPs allele frequency in all donors
In Table 3, there was no significant difference in the
distribution of C and T alleles at rs2280883 of FOXP3
between HCC and healthy donors (P = 0.20), and the fre-
quencies of C and T alleles at rs2280883 were similar in
CHB donors and healthy donors (P = 0.54). The C allele
frequency at rs3761549 was higher in HCC donors than
in healthy donors (OR 1.32; 95% CI 1.03-1.70; P = 0.03),
but there was no significant difference in the distribution
of C and T alleles at rs3761549 between CHB patients
and healthy donors (P = 0.11). The differences in allele
frequencies at rs2280883 and rs3761549 were not ob-
served between CHB donors and HCC donors (P = 0.06,
P = 0.58). These results showed that the C allele at
rs3761549 was associated with HCC but not with CHB.
The association between FOXP3 genotype and
susceptibility to hepatitis B-related HCC
For HCC and healthy donors, the TT genotype at
rs2280883 (OR 1.55; 95% CI 1.11-2.17; P = 0.01) was
more frequent in patients with HCC than the CC or CT
variants, but the frequency of the CC genotype was notprimers





Table 3 The analysis of FOXP3 SNPs allele frequency and genotype in all donors
SNPs HCC n(%) CHB n(%) HEAL n(%) HCC-HEAL CHB-HEAL HCC-CHB
n = 392 n = 344 n = 372 OR(95% CI) P value OR(95% CI) P value OR(95% CI) P value
Allele
rs2280883 0.20 0.54 0.06
C 134(17.1) 144(20.9) 146(19.6) 0.84(0.65-1.10) 1.07(0.87-1.31) 0.78(0.60-1.01)
T 650(82.9) 544(79.1) 598(80.4) 1.18(0.91-1.54) 0.98(0.93-1.04) 1.28(0.99-1.67)
rs3761549 0.03 0.11 0.58
C 630(81.2) 549(80.0) 554(76.5) 1.32(1.03-1.70) 1.05(0.99-1.11) 1.08(0.83-1.40)
T 146(18.8) 137(20.0) 170(23.5) 0.76(0.59-0.97) 0.85(0.70-1.04) 0.93(0.72-1.20)
Genotype
rs2280883 <0.001 <0.01 0.158
CC 54(13.8) 55(16.0) 41(11.0) 1.29(0.84-1.99) 1.54(0.99-2.37) 0.84(0.56-1.26)
TT 312(79.6) 255(74.1) 267(71.8) 1.53(1.10-2.14) 1.13(0.81-1.57) 1.38(0.98-1.95)
CT 26(6.6) 34(9.9) 64(17.2) 0.34(0.21-0.55) 0.53(0.34-0.82) 0.65(0.38-1.10)
rs3761549 <0.001 <0.001 0.239
CC 301(77.6) 256(74.6) 233(64.4) 1.92(1.39-2.64) 1.63(1.18-2.25) 1.18(0.84-1.65)
TT 59(15.2) 50(14.6) 41(11.3) 1.40(0.92-2.15) 1.34(0.86-2.08) 1.05(0.70-1.58)
CT 28(7.2) 37(10.8) 88(24.3) 0.24(0.15-0.38) 0.38(0.25-0.57) 0.64(0.39-1.08)
“HEAL”: Healthy donors.
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(P = 0.249); at rs3761549, the CC genotype (OR 1.92;
95% CI 1.39-2.64; P < 0.001) was more frequent in
patients with HCC than the TT or CT variants, but the
frequency of the TT genotype was not significantly
different between HCC and healthy donors (P = 0.118).
Compared to HCC patients, the CT genotype at both
rs2280883 and rs3761549 was significantly more fre-
quent in healthy donors than the CC or TT variants
(both P < 0.001) (Table 3 and Additional file 1: Table S1).
For CHB donors and healthy donors, the CT genotype at
rs2280883 was more frequent in healthy donors than
the CC or TT variants (P = 0.004), but there were no
significant differences in the distribution of either CC
or TT genotypes between CHB donors and healthy
donors (P = 0.051, P = 0.479); at rs3761549, the CC
genotype (OR 1.63; 95% CI 1.18-2.25; P = 0.003) was
more frequent in patients with CHB than the TT or CT
variants, but there was no significant difference in the
distribution of the TT genotype between CHB donors
and healthy donors (P = 0.198). The CT genotype was
more frequent in healthy donors than the CC and TT vari-
ants (P < 0.001) (Table 3 and Additional file 1: Table S1).
However, there were no significant differences in the
FOXP3 genotype distribution between HCC donors and
CHB donors at either rs2280883 or rs3761549 (Table 3
and Additional file 1: Table S1). Compared to healthy
donors, the TT genotype at rs2280883 was more fre-
quent in patients with HCC, but this genotype
frequency was not significantly different between CHBand healthy donors, in addition, the CC genotype at
rs2280883 was more frequent in CHB patients (16.0%)
than in HCC patients (13.8%), but the TT genotype was
more frequent in HCC patients (79.6%) than in CHB
patients (74.1%); these results showed that the TT geno-
type at rs2280883 was associated with HCC but not
with CHB.
The stratified analysis of the association between FOXP3
genotypes and HCC clinical pathology variables
Because the FOXP3 genetic variants rs2280883 and
rs3761549 were significantly associated with susceptibil-
ity to HCC, further analysis was performed to determine
the relationship between the FOXP3 genotype and mul-
tiple HCC clinical pathology variables, such as age, gen-
der, alcohol abuse history, tumor size, tumor nodule,
tumor grade, lymph node metastasis, portal vein tumor
thrombus, distant metastasis and recurrence. Follow-up
records had not been completed for all of the patients,
and detailed clinical pathology variables were available
for only 188 cases; these details are shown in Table 4. The
CC genotype of rs3761549 was more frequent in HCC
patients with portal vein tumor thrombus (P = 0.02), and
the TT and CT genotypes were more common in patients
with recurrent HCC (P = 0.001).
Discussion
FOXP3 is an accurate marker of primary Tregs in
patients with immune-related disease and cancer [21].
Recently, it was shown that FOXP3 is not only expressed




valuesTT n(%) CC/CT n(%) CC n(%) TT/CT n(%)
n = 151 n = 37 n = 155 n = 33
Age 0.48 0.15
<55 101(66.9) 27(73.0) 109(70.3) 19(57.6)
≥55 50(33.1) 10(27.0) 46(29.7) 14(42.4)
Gender 0.216 0.33
Male 136(90.0) 30(81.1) 139(89.7) 27(81.8)
Female 15(10.0) 7(18.9) 16(10.3) 6(18.2)
Alcohol abuse 0.63 0.80
Absent 72(47.7) 16(43.2) 76(49.0) 17(51.5)
Present 79(52.3) 21(56.8) 79(51.0) 16(48.5)
Tumor Size (cm) 0.61 0.64
≤5 42(27.8) 9(24.3) 44(28.4) 7(21.2)
>5, ≤10 57(37.7) 11(29.7) 54(34.8) 14(42.4)
>10, ≤20 43(28.5) 14(37.9) 48(31.0) 9(27.3)
>20 9(6.0) 3(8.1) 9(5.8) 3(9.1)
Tumor nodule (No.) 0.54 0.48
1 98(64.9) 26(70.3) 104(67.1) 20(60.6)
≥2 53(35.1) 11(29.7) 51(32.9) 13(39.4)
Tumor grade 0.69 0.87
I 24(15.9) 3(8.1) 24(15.5) 3(9.1)
II 24(15.9) 6(16.2) 24(15.5) 6(18.2)
III 97(64.2) 27(73.0) 101(65.2) 23(69.7)
IV 6(4.0) 1(2.7) 6(3.8) 1(3.0)
lymph node metastasis 0.76 0.93
Absent 138(91.4) 35(94.6) 142(91.6) 31(93.9)
Present 13(8.6) 2(5.4) 13(8.4) 2(6.1)
portal vein tumor thrombus 0.76 0.02
Absent 119(78.8) 30(81.1) 118(76.13) 31(93.94)
Present 32(21.2) 7(18.9) 37(23.87) 2(6.06)
Distant Metastasis 0.59 0.73
Absent 136(90.1) 35(94.6) 142(91.6) 29(87.9)
Present 15(9.9) 2(5.4) 13(8.4) 4(12.1)
Recurrence 0.60 0.001
Absent 112(74.2) 29(77.4) 124(80.0) 17(51.5)
Present 39(25.8) 8(21.6) 31(20.0) 16(48.5)
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expression level and function may represent a new
mechanism of immune evasion in cancers [15-17]. Poly-
morphisms of the FOXP3 gene may change FOXP3
quantitatively or functionally, thereby contributing to an
immune imbalance in cancer. To date, polymorphisms
in the FOXP3 gene have been associated with a variety
of immune-related diseases, such as allergic rhinitis [18],
idiopathic infertility and endometriosis-related infertility[19]. However, there are no relevant reports on the rela-
tionship between FOXP3 gene polymorphism and cancer.
Our study aimed to evaluate the association between
FOXP3 gene polymorphisms and hepatitis B-related HCC.
The results showed that the rs2280883 polymorphism was
associated with HCC. Rs2280883, located in intron 9 very
near a conserved gene transcription region of FOXP3,
could cause splicing downstream, resulting in a less func-
tional gene. The rs3761549 polymorphism was also
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satellite, located in the promoter region of the gene, could
theoretically affect gene expression, resulting in FOXP3
mRNA instability. These potential mechanisms need to be
explored.
Based on our study, 92.9% of HCC patients have HBV
infection; it is important to evaluate the association
between FOXP3 gene polymorphism and CHB. Our data
showed that there were also significant differences in
FOXP3 genotype frequencies between CHB donors and
healthy controls; both rs2280883 and rs3761549 polymor-
phisms were related to CHB, but there were no significant
differences in FOXP3 genotype frequencies between CHB
donors and HCC donors at either SNP. These results may
suggest that the FOXP3 gene is involved in both inflam-
mation and tumor pathogenesis or just the process of
inflammation leading to neoplastic transformation; in
contrast, nearly all HCC patients also had hepatitis B, so
FOXP3 polymorphism may create a predisposition to
CHB and cirrhosis, with HCC just a result of this predis-
position. We found that the TT genotype at rs2280883
was more frequent in HCC patients than in CHB patients
compared to healthy donors; this result suggested that the
TT genotype at rs2280883 may be associated with HCC
but not with CHB.
It has previously been reported that high levels of
FOXP3 protein expression are associated with a poor
prognosis and low survival of breast cancer [22].
Whether in Tregs or in tumor cells, FOXP3 expression
plays an immunosuppressive role at the tumor site
[15-17,23]. Taking into account these results for FOXP3
gene function, further analysis showed that the CC
genotype at rs3761549 of FOXP3 was significantly more
frequent in HCC patients with portal vein tumor
thrombus, while the TT and CT genotypes were signifi-
cantly more common in those patients with recurrence.
These results may indicate that FOXP3 has a similar
immunosuppressive effect in liver cancer as in other previ-
ously reported cancers. In addition, it would be interesting
to see portal vein thrombosis incidence in hepatitis B-
related HCC patients in the future; it is possible that this
relationship between FOXP3 rs3761549 genotype and
portal vein thrombosis may hold true and is related to
Hepatitis B virus infection and not HCC itself.
The correlation between FOXP3 gene polymorphisms
and HCV infection is also worth exploring. A previous
study indicated that the microsatellite polymorphisms of
the promoter/enhancer region of FOXP3 were not asso-
ciated with chronic HCV infection [24], and in our
study, we did not receive hepatitis C patients or hepatitis
C-related HCC patients, preventing our discussion of
FOXP3 gene polymorphisms in HCV infection. Current
studies have rarely reported concrete relevance for
FOXP3 expression in tumors; the transcript types andbiological significance of FOXP3 in cancer remains un-
clear. Because of the complex relationship between in-
flammation and a tumor and the important role of FOXP3
in this relationship, it is difficult to clearly describe the
relevance between FOXP3 gene polymorphisms and CHB
or hepatitis B-related HCC.
Overall, our study showed that FOXP3 gene polymor-
phisms are related to hepatitis B-related HCC. Polymor-
phisms at rs2280883 and rs3761549 in the FOXP3 gene
may be associated with CHB and HCC. The existence of
HCC may be related to long-term inflammation due to
CHB. Therefore, more in-depth studies should be
conducted with more samples from a broader population
to further elucidate the molecular mechanism by which
FOXP3 affects the development of HCC.
Additional file
Additional file 1: Table S1. The analysis of FOXP3 SNPs genotypes in
all donors. The 2 × 2 tables were used for two comparisons of genotypes
respectively in HCC patients or CHB patients versus healthy donors, to
get accurate individual P-values.
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